SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid Tuning TM antibody therapeutics that enhance the body’s anti-tumor immunity ...
In less than a decade, bispecific antibodies have gone from scientific curiosity to frontline cancer therapeutics. These engineered proteins, capable of binding to two or more targets simultaneously, ...
Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results